01—Abstract
Summary
Summary of the 8-K filed October 14, 2025. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. filed this Form 8-K on October 14, 2025 under Item 7.01 (Regulation FD Disclosure) to publish a position statement (Exhibit 99.1) on CMS's final IPAY 2028 guidance for Medicare Part B price negotiations under the Inflation Reduction Act.
The statement covers the company's long-term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE® partner product subcutaneous sales. The information is furnished, not filed, for purposes of Section 18 of the Exchange Act. The company's central message is that the final guidance has zero to minimal impact on its future partner royalties.
CMS declined to change its fixed combination drug policy for initial price applicability year 2028 and said it would consider a rulemaking addressing the issue beginning in price applicability year 2029. Halozyme projects zero royalty revenue impact in 2028 and zero to minimal impact in 2029 through 2031 and through at least 2035. The filing attributes these projections to orphan drug exclusions under the One Big Beautiful Bill Act, the potential exclusion of drugs facing biosimilar launches, and the treatment of Darzalex Faspro and Opdivo as orphan-designated products.
The statement also cites a 2025 Journal of Medical Economics study reporting Medicare savings from subcutaneous delivery for 5 of 7 biologic drugs compared with intravenous delivery, and an Oncology and Therapy study in which 89.6%a of surveyed patients preferred subcutaneous delivery versus 5.5% for IV. The filing describes these as supporting evidence rather than a new financial result.
02—Key points
Key Highlights
- CMS final IPAY 2028 guidance keeps the existing fixed combination drug policy unchanged for 2028; CMS will consider a rulemaking on the issue beginning with price applicability year 2029.
- Halozyme projects zero royalty revenue impact from IPAY 2028 Part B negotiations in 2028.
- Halozyme projects zero to minimal royalty revenue impact for 2029, 2030 and 2031, and zero to minimal impact to at least 2035.
- The filing states that U.S. Medicare Part B spend is projected to represent approximately 20% of total ENHANZE® partner product global subcutaneous sales.
- DARZALEX FASPRO® is excluded from Part B negotiations because all of its indications carry orphan designation; Opdivo® is excluded for 2028 because its first indication has orphan designation.
- Halozyme cites a Journal of Medical Economics (2025) study showing subcutaneous delivery of 5 of 7 biologic drugs produced meaningful Medicare savings versus IV, with annualized savings of about $29,000 per patient per year for DARZALEX FASPRO®.
- The filing is a Regulation FD disclosure, and the statement is furnished rather than filed under Section 18 of the Exchange Act.
03—Questions
Frequently Asked Questions
What did CMS decide about fixed combination drugs in the final IPAY 2028 guidance?
CMS said it would not change its fixed combination drug policy in this final guidance because additional time is needed to develop objective criteria. For initial price applicability year 2028, CMS will keep its existing approach, and it intends to address the issue through rulemaking beginning in initial price applicability year 2029.
How much royalty revenue impact does Halozyme project from the IPAY Part B guidance?
Halozyme projects zero royalty revenue impact in 2028 and zero to minimal impact in 2029, 2030 and 2031. It also projects zero to minimal impact to at least 2035, based on orphan drug exclusions, expected biosimilar launches, and the 13-year timing rules for certain approved products.
Why are Darzalex Faspro and Opdivo expected to be insulated from Part B price negotiation?
The filing states that DARZALEX FASPRO® is excluded from Part B negotiations because all of its indications have orphan designation. It says Opdivo® is excluded in 2028 because its first indication has orphan designation, and that its potential price negotiation reduction is projected to be delayed to 2029 unless a biosimilar has launched.
What share of ENHANZE® partner product sales does Medicare Part B represent?
The filing projects that U.S. Medicare Part B spend will represent approximately 20% of total ENHANZE® partner product global subcutaneous sales. The projection uses 2023 Medicare Part B spending data and analyst-based sales estimates.
What evidence does Halozyme cite for the value of subcutaneous delivery?
The filing cites a 2025 Journal of Medical Economics study finding Medicare savings for subcutaneous versus intravenous delivery of 5 of 7 biologic drugs. It also cites a 2025 Oncology and Therapy study in which 89.6% of surveyed patients preferred subcutaneous delivery versus 5.5% for intravenous, and 78.6% were satisfied to very satisfied with subcutaneous delivery versus 33.3% for intravenous.
04—Continue